CXCL1 and breast carcinoma: In breast cancer, MET signaling activates the MAPK pathway and promotes the release of inflammatory cytokines such as IL-1β, IL-8, and CXCL1, thereby reshaping the brain microenvironment and enhancing brain metastasis (23).